Sandercock Colin 4
4 · Cue Biopharma, Inc. · Filed Aug 5, 2020
Insider Transaction Report
Form 4
Sandercock Colin
SVP, GENERAL COUNSEL
Transactions
- Exercise/Conversion
Common Stock
2020-08-03$7.50/sh+6,425$48,188→ 23,550 total - Sale
Common Stock
2020-08-03$20.00/sh−6,425$128,500→ 17,125 total - Sale
Common Stock
2020-08-04$20.05/sh−201$4,030→ 17,125 total - Exercise/Conversion
Stock Option (right to buy)
2020-08-04−201→ 143,374 totalExercise: $7.50Exp: 2024-12-27→ Common Stock (201 underlying) - Exercise/Conversion
Common Stock
2020-08-04$7.50/sh+201$1,508→ 17,326 total - Exercise/Conversion
Stock Option (right to buy)
2020-08-03−6,425→ 143,575 totalExercise: $7.50Exp: 2024-12-27→ Common Stock (6,425 underlying)
Footnotes (4)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 24, 2020.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
- [F4]These Stock Options become exercisable in eight equal semi-annual installments beginning June 5, 2018.